An Open Label, Phase 2 Trial of Orally Administered Bosutinib (SKI-606) in Adult Patients With Recurrent Glioblastoma (GBM).
Phase of Trial: Phase II
Latest Information Update: 22 Jun 2016
At a glance
- Drugs Bosutinib (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 30 Apr 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
- 18 Oct 2013 Planned end date changed from 1 Oct 2012 to 1 Sep 2014 as reported by ClinicalTrials.gov.
- 30 Apr 2012 Additional lead trial investigator (Andrew Norden) identified as reported by ClinicalTrials.gov.